Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 2/20 | 0.51 |
| ▸ | MCL1 | Q07820 | 5/20 | 0.51 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | XDH | P47989 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.45 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.45 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.44 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17502570 | 0.89 | PSMB8 (0.44) | NR4A2MCL1SMPD1NPC1RAB9A | |
| SCHEMBL27843564 | 0.81 | NPC1 (0.58) | MCL1SMPD1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL11005342 | 0.81 | MAPT (0.54) | NPC1RAB9ASMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL13133312 | 0.79 | NR1H4 (0.51) | NR4A2MCL1SMPD1NPC1RAB9A | |
| SCHEMBL3712555 | 0.77 | HDAC1 (0.62) | MCL1NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL1331833 | 0.77 | NR4A2 (0.81) | NR4A2NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL3712561 | 0.76 | MCL1 (0.59) | NR4A2MCL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL28027335 | 0.76 | MAOB (0.48) | NR4A2NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL190703 | 0.75 | MCL1 (0.50) | NR4A2MCL1SMPD1NPC1RAB9A | |
| SCHEMBL6667136 | 0.75 | MAPT (0.51) | MCL1NPC1RAB9ASMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2401263-B1 | SUBSTITUTED AZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITION CONTAINING THE DERIVATIVES, AND METHOD FOR TREATING PARKINSON'S DISEASE USING THE SAME | SK BIOPHARMACEUTICALS CO LTD (KR) | 2016-02-17 | — | — | EP | disclosed |
| CN-102333764-B | The pyrrole derivative replaced, containing the medicinal compositions of these derivatives and treat parkinsonian method with it | SK BIOPHARMACEUTICALS CO.,LTD. (KR) | 2016-01-06 | — | — | CN | disclosed |
| US-8828992-B2 | Substituted azole derivatives, pharmaceutical composition containing the derivatives, and method for treating Parkinson's disease using the same | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2014-09-09 | — | — | US | disclosed |
| CN-102333764-A | Substituted azole derivatives, pharmaceutical composition containing the derivatives, and method for treating parkinson's disease using the same | SK HOLDINGS CO LTD | 2012-01-25 | — | — | CN | disclosed |
| EP-2401263-A2 | SUBSTITUTED AZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITION CONTAINING THE DERIVATIVES, AND METHOD FOR TREATING PARKINSON'S DISEASE USING THE SAME | SK Biopharmaceuticals Co., Ltd. (KR) | 2012-01-04 | — | — | EP | disclosed |
| US-20110301150-A1 | SUBSTITUTED AZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITION CONTAINING THE DERIVATIVES, AND METHOD FOR TREATING PARKINSON'S DISEASE USING THE SAME | SK BIOPHARMACEUTICALS CO., LTD. | 2011-12-08 | — | — | US | disclosed |
| WO-2010098600-A2 | SUBSTITUTED AZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITION CONTAINING THE DERIVATIVES, AND METHOD FOR TREATING PARKINSON'S DISEASE USING THE SAME | SK HOLDINGS CO., LTD. (KR) | 2010-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110301150-A1 | SUBSTITUTED AZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITION CONTAINING THE DERIVATIVES, AND METHOD FOR TREATING PARKINSON'S DISEASE USING THE SAME | MAOB, MAOA, PARK7 | NR4A2 2478/4885MCL1 4046/4885SMPD1 1237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.